Skip to main content

Table 2 Patient characteristics, treatment, and duration of follow up

From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms

Patient # 1 2 3 4 5 6 7 8 9 10
Sex M F M M M F M M M F
Age at Dx, yrs 2.1 3.6 1.5 5.2 5.5 2.4 0.3 3.3 2.3 0.9
# of KD criteria 5 3 2 4 5 4 2 3 4 3
DOI at 1st IVIG tx 4 4 5 8 6 10 6 9 6 8
# of IVIG doses 3 2 3 3 2 2 2 2 2 2
# of IVMP pulses 2 3 1 3 3 0 0 0 0 0
DOI at start of main-tenance IVMP 2 mg/kg/day 23 31 20 16 27 10 6 9 6 8
Other immunomodulatory treatments IFX ×2 IFX IFX, CSA CSA IFX Anakinra None None None None
DOI at CYC 23 and 32 34 20 25 and 37 31 and 38 25 21 13 10 16
# of CYC doses 2 1 1 2 2 1 1 1 1 1
Duration since dx at last follow up 11y 10mo 8 yr 11mo 0.5mo 3 yr 10mo 2 yr 11mo 3 yr 1mo 9mo 1 yr 10mo 3mo 2mo
Initial LAD z score 0.68 NL 6.08 4.66 1.77 13.06 2.96 10.7 13.4 1.85
Initial RCA z score NL NL 1.22 3.05 0.1 5.99 2.92 n/a 2.0 4.0
Max z score at CYC tx, LAD 27.2 29.57 31.27 17.3 19.9 20.35 5.39 10.12 15.5 4.7
Max z score at CYC tx, RCA 22.3 10.5 13.6 13 14.2 7.4 6.67 15.2 2.0 9.8
Max Z score at last follow up, LAD 13.5 1.13 31.1 0.56 5.0 13.9 1.02 1.16 7.7 0.4
Max Z score at last follow up, RCA 28.5 0.12 13.5 7.32 6.0 1.1 1.78 19.0 1.3 4.1
  1. Yrs years, tx treatment, DOI day of illness, IVIG intravenous immunoglobulin, IVMP intravenous methylprednisolone, IFX infliximab, CSA cyclosporine A, CYC cyclophosphamide, LAD left anterior descending (proximal), RCA right coronary artery, CA coronary artery dimensions; Normalα: z score ≤ 2; CAAβ: coronary artery aneurysms, z > 2.5
\